Source comparison
MK-677 50s Age Specific Protocol: Comparison
25–35 years 20–25mg daily Minimal. Insulin sensitivity high, beta-cell reserve robust Baseline + week 12 labs sufficient 16–20 weeks on, 4 weeks off Standard protocols work well; metabolic tolerance high 36–49 years 15–20mg daily Moderate. Early insulin resist
This comparison does not assign a generated winner or score.
- 25–35 years
- 20–25mg daily
- Minimal. Insulin sensitivity high, beta-cell reserve robust
- Baseline + week 12 labs sufficient
- 16–20 weeks on, 4 weeks off
- Standard protocols work well; metabolic tolerance high
- 36–49 years
- 15–20mg daily
- Moderate. Early insulin resistance developing, glucose disposal slowing
- Baseline + week 6 + week 12
- 12–16 weeks on, 4–6 weeks off
- Dose reduction begins to matter; monitor glucose closely
- 50–60 years
- 10–15mg daily
- High. Insulin resistance established, cardiovascular risk elevated
- Baseline + week 2 + week 8 + week 12
- 12 weeks on, 6 weeks off
- Lower dose yields similar IGF-1 response with significantly reduced metabolic strain
- 60+ years
- 5–10mg daily
- Very high. Beta-cell function declining, edema risk compounds
- Baseline + biweekly glucose monitoring
- 8–10 weeks on, 8 weeks off
- Benefit-to-risk ratio narrows; clinical oversight essential